您当前所在的位置:首页 > 产品中心 > 产品信息
Ergoloid mesylate_分子结构_CAS_8067-24-1)
点击图片或这里关闭

Ergoloid mesylate

产品号 DB01049 公司名称 DrugBank
CAS号 8067-24-1 公司网站 http://www.ualberta.ca/
分子式 C33H45N5O5 电 话 (780) 492-3111
分子量 591.7409 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 921

产品价格信息

请登录

产品别名

标题
Ergoloid mesylate
IUPAC标准名
N-[2-hydroxy-7-(2-methylbutan-2-yl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
IUPAC传统名
CO-dergocrine mesylate
商标名
Hydergine
Hydergine LC
Dihydroergotoxin Methanesulfonate
Deapril-ST
Ischelium
Hydrogenated Ergot Alkaloids
Redergin
Trigot
Alkergot
Co-Dergocrine Mesylate
Dihydroergotoxin Mesilat
Dihydroergotoxin Mesylate
Dihydroergotoxine Methanesulphonate
Ergoloid Mesylates [Usan]
Gerimal
Hydergin
Circanol
Dihydroergotoxine Mesilate
Dihydroergotoxine Mesylate
Dihydroergotoxine Methanesulfonate

产品登记号

CAS号 8067-24-1

产品性质

疏水性(logP) 2.8

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Ergoloid mesylate is a dihydrogenated ergot (Claviceps purpurea) derivative alkaloid used as a vasodilator agent. Ergoloid Mesylate is the only vasodilator that has shown mild benefits in the treatment of vascular dementia.
Indication For use as an adjunct therapy for patients with dementia
Pharmacology Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.
Toxicity Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic.
Absorption Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
Half Life 3.5 hours
Protein Binding 98-99%
External Links
Wikipedia

参考文献